| Literature DB >> 29026428 |
Krzysztof Kowalski1, Paweł Marciniak2, Grzegorz Rosiński2, Leszek Rychlik1.
Abstract
BACKGROUND: Animal toxins can have medical and therapeutic applications. Principally, toxins produced by insects, arachnids, snakes and frogs have been characterized. Venomous mammals are rare, and their venoms have not been comprehensively investigated. Among shrews, only the venom of Blarina brevicauda has been analysed so far, and blarina toxin has been proven to be its main toxic component. It is assumed that Neomys fodiens employs its venom to hunt larger prey. However, the toxic profile, properties and mode of action of its venom are largely unknown. Therefore, we analysed the cardio-, myo- and neurotropic properties of N. fodiens venom and saliva of non-venomous Sorex araneus (control tests) in vitro in physiological bioassays carried out on two model organisms: beetles and frogs. For the first time, we fractionated N. fodiens venom and S. araneus saliva by performing chromatographic separation. Next, the properties of selected compounds were analysed in cardiotropic bioassays in the Tenebrio molitor heart.Entities:
Keywords: Mammalian venom; Natural toxins; Neomys fodiens; Salivary glands; Shrews; Sorex araneus; Toxicity in vitro
Year: 2017 PMID: 29026428 PMCID: PMC5622582 DOI: 10.1186/s12983-017-0230-0
Source DB: PubMed Journal: Front Zool ISSN: 1742-9994 Impact factor: 3.172
Fig. 1Decrease in the heartbeat frequency after the application of N. fodiens venom (NF) and S. araneus saliva (SA). a Treatment of the T. molitor heart with 10 μl of N. fodiens venom extract and 10 μl of S. araneus saliva. b Treatment of the frog heart with 40 μl of venom or saliva (registration of the heart contractile activity for 2 min). Statistically significant differences are indicated by asterisks (NF: Wilcoxon-test in a, n = 32; paired Student’s t-test in b, n = 30; SA: paired Student’s t-test in a, n = 40; Wilcoxon-test in b, n = 30) for intraspecific comparisons (*** p < 0.001) and black dots (unpaired Student’s t-test) for comparisons between NF and SA (• p < 0.05)
Fig. 2Cardiomyograms displaying changes in the T. molitor heartbeat frequency after treatment with N. fodiens venom and S. araneus saliva. a Application of 10 μl of venom extract of N. fodiens. b Application of fraction no. 5 from N. fodiens venom. c Treatment with 10 μl of saliva extract of S. araneus. The sample application is indicated by an arrow
Fig. 3Cardiomyograms displaying changes in the frog heartbeat frequency after treatment with N. fodiens venom and S. araneus saliva. The heart activity after application of 40 μl of Ringer’s solution (control) (a, c), N. fodiens venom (in the 1st minute) (b), and S. araneus saliva (in the 1st minute) (d). The sample application is indicated by an arrow
Fig. 4Chromatograms displaying separation of the methanolic extract of the saliva of N. fodiens (a) and S. araneus (b). The analysed fractions are indicated by arrows
Fig. 5Effects of fractions from N. fodiens venom (a) and S. araneus saliva (b) on the T. molitor heartbeat frequency. Statistically significant changes in the heart contractile activity are indicated by asterisks (Wilcoxon-test after Bonferroni correction: * p’ < 0.05, ** p’ < 0.01)
Fig. 6Changes in the contraction force of the frog calf muscle (a) and sciatic nerve conduction velocity (b). In both tests, 40 μl of extract from N. fodiens venom (NF) and 40 μl of S. araneus saliva (SA) were applied. Statistically significant differences are indicated by asterisks (NF: paired Student’s t-test in a, n = 30; Wilcoxon-test in b, n = 32; SA: Wilcoxon-test in a, n = 30; paired Student’s t-test in b, n = 30) for intraspecific comparisons (* p < 0.05, *** p < 0.001) and black dots (a: Mann-Whitney U-test; b: unpaired Student’s t-test in 0 min and Mann-Whitney U-test in 1 min after) for comparisons between NF and SA (• p < 0.05, ••• p < 0.001)
Pre-identification of proteins from N. fodiens venom and S. araneus saliva based on tandem mass spectrometry analysis
| Sample | Protein name | Species | Accession | Matched peptides | Protein sequence coverage [%] | Ion score | m/z | Identified peptides | Possible toxic activity |
|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
| extract | calmodulin-like protein |
| Q9D6P8 | 25 | 37 | 64 | 955 | K.EAFSLFDK.D | Acute and chronic effects on cardiac function by regulation of the intracellular Ca2+ concentration [ |
| 37 | 4086 | R.SLGQNPTEAELQGMVNEIDKDGNGTVDFPEFLTMMSR.K + Oxidation (M) | |||||||
| 57 | 4102 | R.SLGQNPTEAELQGMVNEIDKDGNGTVDFPEFLTMMSR.K + 2 Oxidation (M) | |||||||
| 97 | 1351 | K.MKDTDSEEEIR.E | |||||||
| 81 | 1367 | K.MKDTDSEEEIR.E + Oxidation (M) | |||||||
| 65 | 1092 | K.DTDSEEEIR.E | |||||||
| hyaluronidase-2 |
| Q8SQG8 | 14 | 8 | 24 | 980 | HKMPLDPK | Facilitates spread of other venom proteins [ | |
| thymosin β-10 |
| P21752 | 11 | 11 | 22 | 862 | KTETQEK | Improves cardiac function, promotes vascularization and contractility in heart tissue [ | |
| β-nerve growth factor |
| P01139 | 8 | 6 | 68 | 1153 | K.LQHSLDTALR.R | Unknown [ | |
| 37 | 764 | R.RLHSPR.V | |||||||
| fraction no. 5 | cystatin-C |
| P14841 | 14 | 8 | 28 | 1207 | GTHTLTKSSCK | Inhibits cysteine proteases, failures in biological mechanisms controlling protease activities may led to many diseases such as neuro-degeneration or cardiovascular diseases [ |
| coagulation factor VIII |
| P12263 | 18 | 5 | 22 | 1427 | ISALGKSAAGPLASGK | Acts as an anti-hemophilic factor [ | |
| lysozyme C-1 |
| P12067 | 6 | 8 | 24 | 930 | YWCNDGK | Involved in an antimicrobial defence [ | |
| fraction no. 31 | hyaluronidase PH-20 |
| gi|521028001 | 14 | 11 | 47 | 1152 | KDIEFYIPK | See above |
| fraction no. 34 | chain E, leech-derived tryptase inhibitor Trypsin Complex |
| gi|3318722 | 48 | 21 | 177 | 2210 | R.LGEHNIDVLEGNEQFINAAK.I | Prolongs the blood clotting time by thrombin and trypsin inhibition [ |
| 115 | 2282 | K.IITHPNFNGNTLDNDIMLIK.L | |||||||
| 93 | 1045 | K.LSSPATLNSR.V | |||||||
| 77 | 841 | R.VATVSLPR.S | |||||||
| 108 | 1515 | K.SSGSSYPSLLQCLK.A | |||||||
| 98 | 1051 | K.APVLSDSSCK.S | |||||||
| fraction no. 39 | coagulation factor VIII |
| P12263 | 19 | 7 | 23 | 1427 | ISALGKSAAGPLASGK | See above |
| lactyloglutathione lyase |
| Q6P7Q4 | 17 | 25 | 78 | 1264 | K.DFLLQQTMLR.I | Involved in inflammation [ | |
| 54 | 1028 | K.KSLDFYTR.V | |||||||
| 44 | 900 | K.SLDFYTR.V | |||||||
| 57 | 976 | K.RFEELGVK.F | |||||||
| 65 | 2288 | K.GLAFVQDPDGYWIEILNPNK.M | |||||||
| fraction no. 40 | phospholipase A2 |
| P14422 | 6 | 6 | 27 | 1002 | FAKFLSYK | Exhibits cardio-, myo- and neurotoxicity, as well as pro- and anticoagulant effects [ |
| calmodulin-like protein |
| Q9D6P8 | 14 | 5 | 25 | 1367 | MKDTDSEEEIR | See above | |
|
| |||||||||
| extract | thymosin β-10 |
| P63312 | 7 | 34 | 56 | 862 | K.KTETQEK.N | See above |
| 37 | 734 | K.TETQEK.N | |||||||
| 48 | 875 | K.ETIEQEK.R | |||||||
| 77 | 1031 | K.ETIEQEKR.S | |||||||
| coagulation factor XI |
| Q91Y47 | 10 | 11 | 21 | 846 | MICAGYK | Involved in blood clotting [ | |
| fraction no. 23 | thymosin β-4 |
| P34032 | 69 | 88 | 46 | 1245 | M.ADKPDMAEIEK.F | See thymosin β-10 |
| 47 | 1652 | M.ADKPDMAEIEKFDK.S + Oxidation (M) | |||||||
| 34 | 862 | K.KTETQEK.N | |||||||
| 38 | 734 | K.TETQEK.N | |||||||
| 83 | 1371 | K.TETQEKNPLPSK.E | |||||||
| 89 | 1512 | K.NPLPSKETIEQEK.Q | |||||||
| 43 | 875 | K.ETIEQEK.Q | |||||||
| 72 | 1348 | K.ETIEQEKQAGES.- | |||||||
| cystatin-C |
| P14841 | 14 | 8 | 27 | 1207 | GTHTLTKSSCK | See above | |
| fraction no. 28 | cystatin-C |
| P14841 | 11 | 6 | 43 | 1207 | K.GTHTLTKSSCK.N | See above |
| lysozyme C-1 |
| P12067 | 10 | 19 | 22 | 787 | AWVAWR | See above | |
| kallikrein 1-related peptidase b24 |
| Q61754 | 10 | 6 | 33 | 1204 | K.DKSNDLMLLR.L | Might act as an inflammatory agent (increasing vascular permeability and lowering blood pressure) [ | |
| fraction no.29 | cystatin-C |
| P14841 | 14 | 8 | 27 | 1207 | GTHTLTKSSCK | See above |
| α-amylase 1 |
| P00687 | 8 | 11 | 25 | 780 | DYVRTK | Unknown | |
| β-defensin 7 |
| Q91V70 | 8 | 11 | 24 | 760 | FQIPEK | Exhibits a significant myo- and neurotoxic activity, modifying voltage-sensitive Na+ channels, resulting in a potent analgesic effect [ | |